245 related articles for article (PubMed ID: 17069803)
1. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
Kieseier BC; Hartung HP
Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
[No Abstract] [Full Text] [Related]
2. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
Biernacki K; Antel JP; Blain M; Narayanan S; Arnold DL; Prat A
Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253
[TBL] [Abstract][Full Text] [Related]
3. Translating new insights into treatment optimisation in multiple sclerosis.
Fazekas F; Kieseier BC
J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857
[No Abstract] [Full Text] [Related]
4. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
Banwell B; Tremlett H
Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
[No Abstract] [Full Text] [Related]
5. Linkage between immunomodulation, neuroprotection and neurogenesis.
Aharoni R; Arnon R
Drug News Perspect; 2009; 22(6):301-12. PubMed ID: 19771319
[TBL] [Abstract][Full Text] [Related]
6. The future of multiple sclerosis treatment.
Cohen JA
J Neurol Sci; 2009 Feb; 277 Suppl 1():S55-61. PubMed ID: 19200869
[TBL] [Abstract][Full Text] [Related]
7. Approaches to neuroprotective strategies in multiple sclerosis.
Tselis A; Khan OA; Lisak RP
Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779
[TBL] [Abstract][Full Text] [Related]
8. Future neuroprotective strategies.
Sättler MB; Bähr M
Exp Neurol; 2010 Sep; 225(1):40-7. PubMed ID: 19716365
[TBL] [Abstract][Full Text] [Related]
9. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
Taoufik E; Tseveleki V; Euagelidou M; Emmanouil M; Voulgari-Kokota A; Haralambous S; Probert L
Neurodegener Dis; 2008; 5(1):32-7. PubMed ID: 18075273
[TBL] [Abstract][Full Text] [Related]
10. Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J; Lublin FD
Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
[No Abstract] [Full Text] [Related]
11. 'Time is brain' also in multiple sclerosis.
Freedman MS
Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740
[No Abstract] [Full Text] [Related]
12. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
Aktas O; Kieseier B; Hartung HP
Trends Neurosci; 2010 Mar; 33(3):140-52. PubMed ID: 20045200
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta1a treatment for multiple sclerosis.
Sandberg-Wollheim M
Expert Rev Neurother; 2005 Jan; 5(1):25-34. PubMed ID: 15853471
[TBL] [Abstract][Full Text] [Related]
14. Experimental models of neuroprotection relevant to multiple sclerosis.
Yong VW; Giuliani F; Xue M; Bar-Or A; Metz LM
Neurology; 2007 May; 68(22 Suppl 3):S32-7; discussion S43-54. PubMed ID: 17548566
[TBL] [Abstract][Full Text] [Related]
15. Treatment of multiple sclerosis patients with interferon-beta primes monocyte-derived macrophages for apoptotic cell death.
Van Weyenbergh J; Wietzerbin J; Rouillard D; Barral-Netto M; Liblau R
J Leukoc Biol; 2001 Nov; 70(5):745-8. PubMed ID: 11698494
[TBL] [Abstract][Full Text] [Related]
16. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
[TBL] [Abstract][Full Text] [Related]
17. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
Gout O
Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
[No Abstract] [Full Text] [Related]
18. Interferon-beta for multiple sclerosis: Long-term benefits?
Rudick RA; Cutter G
Ann Neurol; 2007 Apr; 61(4):283-5. PubMed ID: 17444503
[No Abstract] [Full Text] [Related]
19. Current trends in multiple sclerosis research: an update on pathogenic concepts.
Vanderlocht J; Hellings N; Hendriks JJ; Stinissen P
Acta Neurol Belg; 2006 Dec; 106(4):180-90. PubMed ID: 17323836
[TBL] [Abstract][Full Text] [Related]
20. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
Thrower BW
Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
